Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer cell subpopulations responsible for early relapses, new study shows

This article was originally published in Scrip

Executive Summary

Tumour cell heterogeneity may mean that individual cancers are already inherently resistant to current drug therapies before treatment begins, according to a small study in cervical cancer from researchers at Cancer Research UK institutes in Cambridge and Edinburgh. Lead study author, Dr Susanna Cooke, explained that genotyping of biopsies taken from cervical tumours shows that more than one type of cell may be present when the treating physician first sees the disease. Subsequent treatment can drastically reduce the quantity of susceptible cells, but the residual population of cells then grows through, causing rapid, therapy-resistant remission.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC011539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel